Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: A risk of opportunistic infection after treatment with anti-CCR4 antibodies

摘要

Human T cell leukemia virus type I (HTLV-I) is a human retrovirus that is an etiologic agent of adult T cell leukemia/lymphoma (ATL/ATLL) [1]. Adult ATL/ATLL is an aggressive lymphoid neoplasm associated with HTLV-1 [2]. The CC-chemokine receptor 4 (CCR4) is expressed in almost all ATLL cells [3, 4]. Thus, anti-CCR4 antibodies can be used as a treatment strategy for ATLL. Mogamulizumab (MOG), which is a defucosylated anti-CCR4 monoclonal antibody, showed good results even in patients with recurrent ATLL in phase I or II studies [5, 6]. In a phase II study of MOG for ATLL, the overall response rate was 50 % and progression-free survival and overall survival were also significantly improved [5].